Evaluation of Recombinant Human Platelet Derived Growth Factor (rhPDGF-BB) Along with Tricalcium Phosphate (β-TCP) in Impacted Mandibular 3rd Molar Sockets

Abstract

Aim: The aim of this study was to evaluate efficacy of Recombinant Human Platelet derived Growth Factor (rhPDGF-BB) mixed with Tricalcium Phosphate (β-TCP) particles in mandibular 3rd molar extraction socket for bone regeneration. Setting And Design: A comparative clinical trial consisting of 10 patients who wanted to undergo the surgical extraction of mandibular 3rd molar bilaterally, were undertaken in the institutional settings, where in each patient one side of lower third molar extraction site was kept as control and in the other side graft material was used, after the approval from the institutional ethical committee. Materials And Methods: In this study 10 patients were included with mean age of 28.3 years (Ranging from (20-35 years). These were 4 male and 6 female patients. In each patient one side of lower third molar extraction site was kept as control site and in the other side graft material was used kept as study site. Hence 10 control sites were compared with 10 study sites. Selection of site for placement of graft was done randomly. In 6 patients study site was on right side and in 4 patients study site was on left side. Clinical parameters like pain, facial swelling, total number of analgesic tablets required evaluated at 48hrs and at 7th day. While, radiographically bone density was evaluated after 1st and 3rd month postoperatively. Other parameters like infection, sinus discharge, wound dehiscence, dry socket or graft leakage were also observed. Results: rh PDGF with β – TCP when used in mandibular third molar extraction socket results in rapid bone regeneration seen via increased bone density. It also results in less post-operative discomfort to the patient like pain and swelling. Complications like infection, sinus discharge, wound dehiscence, dry socket or graft leakage were not encountered and the tissue showed good acceptance with no graft rejection. Conclusions: The rh PDGF/β – TCP combination is a novel bone grafting material with excellent results and should be included in the armamentarium when bone defect is encountered.